Tumor necrosis factor-α and CD95 ligation suppress erythropoiesis in Fanconi anemia C gene knockout mice

Journal of Cellular Physiology

Volumn 179, Issue 1, 1999, Pages 79-86

  Otsuki, Tetsuya ^a   Nagakura, Shoichi ^a   Wang, Jianxiang ^a   Bloom, Michael ^a   Grompe, Markus ^b   Liu, Johnson M ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ARTICLE; ERYTHROPOIESIS; FANCONI ANEMIA; GENE MUTATION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0032976437     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4652(199904)179:1<79::AID-JCP10>3.0.CO;2-O     Document Type: Article

References (47)

1. Akahane K, Hosoi T, Urabe A. Kawakami M, Takaku F. 1987. Effect of recombinant human tumor necrosis factor (rhTNF) on normal human and mouse hemopoietic progenitor cells. Int J Cell Cloning 5:16-26.
2. Auerbach AD, Verlander PC. 1997. Disorder of DNA replication and repair. Curr Opin Pediatr 9:600-616.
3. Auerbach AD, Rogatko A, Schroeder-Kurth TM. 1989. International Fanconi anemia registry: relation of clinical symptoms to diepoxybutane sensitivity. Blood 73:391-396.
4. Barcena A, Park SW, Banapour B, Muench MO, Mechetner E. 1996. Expression of Fas/CD95 and Bcl-2 by primitive hematopoietic progenitors freshly isolated from human fetal liver. Blood 88:2013-2025.
5. Bazzoni F, Beutler B. 1996. The tumor necrosis factor ligand and receptor families. N Engl J Med 334:1717-1725.
6. Blick M, Sherwin SA, Rosenblum M, Gutterman J. 1987. Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res 47:2986-2989.
7. Broxmeyer HE, Williams DE, Lu L, Cooper S, Anderson SL, Beyer GS, Hoffman R, Rubin BY. 1986. The suppressive influences of human tumor necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: synergism of tumor necrosis factor and interferons-γ. J Immunol 136: 4487-4495.
8. Chen M, Tomkins DJ, Auerbach W, McKerlie C, Youssoufian H, Liu L, Gan O, Carreau M, Auerbach A, Groves T, Guidos CJ, Freedman MH, Cross J, Percy DH, Dick JE, Joyner AL, Buchwald M. 1996. Inactivation of Fac in mice produces inducible chromosomal instability and reduced fertility reminiscent of Fanconi anaemia. Nature Genet 12:448-451.
9. Gumming RC, Liu JM, Youssoufian H, Buchwald M. 1996. Suppression of apoptosis in hematopoietic factor-dependent progenitor cell lines by expression of the FAC gene. Blood 88:4558-4567.
10. Dai C-H, Price JO, Brunner T, Krantz SB. 1998. Fas ligand is present in human erythroid colony-forming cells and interacts with Fas induced by interferon to produce erythroid cell apoptosis. Blood 91:1235-1242.
11. D'Andrea AD, Grompe M. 1997. Molecular biology of Fanconi anemia: implications for diagnosis and therapy. Blood 90:1725-1736.
12. Fanconi Anaemia/Breast Cancer Consortium. 1996. Positional cloning of the Fanconi anaemia group A gene. Nature Genet 14:324-328.
13. Haneline LS, Broxmeyer HE, Cooper S, Hangoc G, Carreau M, Buchwald M, Clapp DW. 1998. Multiple inhibitory cytokines induce deregulated progenitor growth and apoptosis in hematopoietic cells from fac -/- mice. Blood 91:4092-4098.
14. Joenje H, Lo Ten Foe JR, Oostra AB, van Berkel CGM, Rooimans MA, Schroeder-Kurth T, Wegner R-D, Gille JJP, Buchwald M, Arwert F. 1995. Classification of Fanconi anemia patients by complementation analysis: evidence for fifth genetic subtype. Blood 86:2156-2160.
15. Joenje H, Oostra AB, Wijker M, di Summa FM, van Berkel CG, Rooimans MA, Ebell W, van Weel M, Pronk JC, Buchwald M, Arwert F. 1997. Evidence for at least eight Fanconi anemia genes. Am J Hum Genet 61:940-944.
16. Johnson RA, Waddelow TA, Caro J, Oliff CA, Roodman GD. 1989. Chronic exposure to tumor necrosis factor in vivo preferentially inhibits erythropoiesis in nude mice. Blood 74:130-138.
17. Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, Kollias G. 1991. Transgenic mice expressing human tumor necrosis factor: a predictive genetic model of arthritis. EMBO J 10: 4025-4031.
18. Kruyt FAE, Dijkmans LM, van den Berg TK, Joenje H. 1996. Fanconi anemia genes act to suppress a cross-linker-inducible p53-independent apoptosis pathway in lymphoblastoid cell lines. Blood 87:938-948.
19. Kupfer GM, D'Andrea AD. 1996. The effect of the Fanconi anemia polypeptide, FAC, upon p53 induction and G2 checkpoint regulation. Blood 88:1019-1025.
20. Laquerbe A, Moustacchi E, Fuscoe JC, Papadopoulo D. 1995. The molecular mechanism underlying formation of deletions in Fanconi anemia cells may involve a site-specific recombination. Proc Natl Acad Sci USA 92:831-835.
21. Lin G, Finger E, Gutierrez-Ramos JC. 1995. Expression of CD34 in endothelial cells, hematopoietic progenitors and nervous cells in fetal and adult mouse tissues. Eur J Immunol 25:1508-1516.
22. Liu JM, Buchwald M, Walsh CE, Young NS. 1994. Fanconi anemia and novel strategies for therapy. Blood 84:3995-4007.
23. Lo Ten Foe JR, Rooimans MA, Bosnoyan-Collins L, Alon N, Wijker M, Parker L, Lightfoot J, Carreau M, Callen D, Savoia A, Cheng NC, van Berkel CGM, Strunk MHP, Gille JJP, Pals G, Kruyt FAE, Pronk JC, Arwert F, Buchwald M, Joenje H (1996) Expression cloning of a cDNA for the major Fanconi anaemia gene, FAA. Nature Genet 14:320-323.
24. Maciejewski J, Selleri C, Anderson S, Young NS. 1995. Fas antigen expression on CD34+ human marrow cells is induced by interferon and tumor necrosis factor and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood 85:3183-3190.
25. Muller M, Strand S, Hug H, Heinemann E-M, Walczak H, Hofmann JW, Stremmel W, Krammer P, Galle PR. 1997. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (Apo-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest 99:403-413.
26. Murase T, Hotta T, Saito H, Ohno R. 1987. Effect of recombinant human tumor necrosis factor on the colony growth of human leukemia progenitor cells and normal hematopoietic progenitor cells. Blood 69:467-472.
27. Nagafuji K, Shibuya T, Harada M, Mizuno S, Takenaka K, Miyamoto T, Okumura T, Gondo H, Niho Y. 1995. Functional expression of Fas antigen (CD95) on hematopoietic progenitor cells. Blood 86: 883-889.
28. Nagata S, Golstein P. 1995. The Fas death factor. Science 267:1449-1455.
29. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, Itoh N, Suda T, Nagata S. 1993. Lethal effect of the anti-Fas antibody in mice. Nature 364:806-809.
30. Owen-Schaub LB, Zhang W, Cusack JC, Angelo LS, Santee SM, Fujiwara T, Roth JA, Deisseroth AB, Zhang W-W, Kruzel E, Radinsky R. 1995. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol 15:3032-3040.
31. Rathbun RK, Faulkner GR, Ostroski MH, Christianson TA, Hughes G, Jones G, Cahn R, Maziarz R, Royle G, Keeble W, Heinrich MC, Grompe M, Tower PA, Bagby GC. 1997. Inactivation of the Fanconi anemia group C gene augments interferon-γ-induced apoptotic responses in hematopoietic cells. Blood 90:974-985.
32. Reap EA, Roof K, Maynor K, Borrero M, Booker J, Cohen PL. 1997. Radiation and stress-induced apoptosis: a role for Fas/Fas ligand interactions. Proc Natl Acad Sci USA 94:5750-5755.
33. Rosselli F, Sanceau J, Gluckman E, Wietzerbin J, Moustacchi E. 1994. Abnormal lymphokine production: a novel feature of the genetic disease Fanconi anemia. II. In vitro and in vivo spontaneous overproduction of tumor necrosis factor α. Blood 83:1216-1225.
34. Schultz JC, Shahidi NT. 1993. Tumor necrosis factor-α overproduction in Fanconi's anemia. Am J Hematol 42:196-201.
35. Segal GM, Magenis RE, Brown M, Keeble W, Smith TD, Heinrich MC, Bagby GC. 1994. Repression of Fanconi anemia gene (FACC) expression inhibits growth of hematopoietic progenitor cells. J Clin Invest 94:846-852.
36. Sheard MA, Vojtesek B, Janakova L, Kovarik J, Zaloudik J. 1997. Up-regulation of Fas (CD95) in human p53 wild-type cancer cells treated with ionizing radiation. Int J Cancer 73:757-762.
37. Strathdee CA, Gavish H, Shannon WR, Buchwald M. 1992. Cloning of cDNA for Fanconi's anemia by functional complementation. Nature 356:763-767.
38. Suda T, Tanaka M, Miwa K, Nagata S. 1996. Apoptosis of mouse naive T cells induced by recombinant soluble Fas ligand and activation-induced resistance to Fas ligand. J Immunol 157:3918-3924.
39. Suda T, Hashimoto H, Tanaka M, Ochi T, Nagata S. 1997. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas blocks the killing. J Exp Med 186:2045-2050.
40. Walsh CE, Grompe M, Vanin E, Buchwald M, Young NS, Nienhuis AW, Liu JM. 1994. A functionally active retrovirus vector for gene therapy in Fanconi anemia group C. Blood 84:453-459.
41. Wang J, Otsuki T, Youssoufian H, Lo Ten Foe J, Kirn S, Devetten M, Yu J, Li Y, Dunn D, Liu JM. 1998. Overexpression of the Fanconi anemia group C gene (FAC) protects hematopoietic progenitors from death induced by Fas-mediated apoptosis. Cancer Res 58: 3538-3541.
42. Wevrick R, Clarke CA, Buchwald M. 1993. Cloning and analysis of the murine Fanconi anemia group C cDNA. Hum Mol Genet 2:655-662.
43. Whitney MA, Royle G, Low MJ, Kelly MA, Axthelm MK, Reifsteck C, Olson S, Braun RE, Heinrich MC, Rathbun RK, Bagby GC, Grompe M. 1996. Germ cell defects and hematopoietic hypersensitivity to γ-interferon in mice with a targeted disruption of the Fanconi anemia C gene. Blood 88:49-58.
44. Young NS, Maciejewski J. 1997. The pathophysiology of acquired aplastic anemia. N Engl J Med 336:1365-1372.
45. Young PE, Baumheuter S, Lasky LA. 1995. The sialomucin CD34 is expressed on hematopoietic cells and blood vessels during murine development. Blood 85:96-105.
46. Zeigler FC, Bennett BD, Jordan CT, Spencer SD, Baumheuter S, Carroll KJ, Hooley J, Bauer K, Matthews W. 1994. Cellular and molecular characterization of the role of the FLK-2/FLT-3 receptor tyrosine kinase in hematopoietic stem cells. Blood 84:2422-2430.
47. Zhang Y, Hanada A, Bluethmann H, Wang J-B, Nakao S, Mukaida N, Matsushima K. 1995. Tumor necrosis factor (TNF) is a physiologic regulator of hematopoietic progenitor cells: increase of early hematopoietic progenitor cells in TNF receptor p55-deficient mice in vivo and potent inhibition of progenitor cell proliferation by TNF in vitro. Blood 86:2930-2937.